Bionano Genomics narrows Q1 loss to $0.76 and records flow cell sales
Bionano Genomics posted a Q1 net loss of $0.76 per share, beating estimates by $0.05 and improving from a $1.15 loss a year earlier. The company also reported record flow cell sales, reflecting rising demand for its optical genome mapping consumables.
1. Q1 Financial Performance
Bionano Genomics reported a net loss of $0.76 per share in Q1 2026, outperforming the consensus estimate of a $0.81 loss and improving significantly from a $1.15 loss in the year-ago quarter. Revenue also topped analyst forecasts, underscoring a trend of steady top-line growth.
2. Record Flow Cell Sales
The company achieved record sales of flow cells during the quarter, driven by increased adoption of its Saphyr optical genome mapping system across research and clinical applications. Management attributed the surge to expanded distribution agreements and renewed customer orders.
3. Management Commentary
Executives highlighted efficiency gains from cost-control measures and noted progress toward profitability, with operating expenses held flat despite higher sales volumes. They reiterated focus on strategic partnerships and product pipeline advancement to sustain momentum into the second half of the year.